S
Stefania Cuzzubbo
Researcher at University of Paris
Publications - 16
Citations - 728
Stefania Cuzzubbo is an academic researcher from University of Paris. The author has contributed to research in topics: Medicine & Immune system. The author has an hindex of 6, co-authored 13 publications receiving 388 citations.
Papers
More filters
Journal ArticleDOI
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature.
Stefania Cuzzubbo,F. Javeri,M. Tissier,A Roumi,Ciprian Barlog,Jennifer Doridam,Céleste Lebbé,Catherine Belin,Renata Ursu,Antoine F. Carpentier +9 more
TL;DR: In most cases, drug interruption and steroids led to neurological recovery, even in conditions where steroids are not usually recommended such as Guillain-Barré syndrome, and the median time of nAEs onset was 6 weeks.
Journal ArticleDOI
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).
Thomas Cluzeau,Marie Sebert,Ramy Rahmé,Stefania Cuzzubbo,Jacqueline Lehmann-Che,Isabelle Madelaine,Pierre Peterlin,Blandine Beve,Habiba Attalah,Fatiha Chermat,Elsa Miekoutima,Odile Beyne Rauzy,Christian Recher,Aspasia Stamatoullas,Lise Willems,Emmanuel Raffoux,Céline Berthon,Bruno Quesnel,Michael Loschi,Antoine F. Carpentier,David A. Sallman,Rami S. Komrokji,Anouk Walter-Petrich,Sylvie Chevret,Lionel Ades,Pierre Fenaux +25 more
TL;DR: PURPOSETP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment received, including 40% responses (20% complete removals).
Journal ArticleDOI
APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)
Thomas Cluzeau,Thomas Cluzeau,Marie Sebert,Ramy Rahmé,Stefania Cuzzubbo,Anouk Walter-Petrich,Jacqueline Lehmann che,Pierre Peterlin,Blandine Beve,Habiba Attalah,Fatiha Chermat,Elsa Miekoutima,Odile Beyne-Rauzy,Christian Recher,Aspasia Stamatoullas,Lise Willems,Emmanuel Raffoux,Céline Berthon,Bruno Quesnel,Antoine F. Carpentier,David A. Sallman,Sylvie Chevret,Lionel Ades,Pierre Fenaux +23 more
TL;DR: The combination of AZA and APR 246 showed promising results in a phase Ib study in TP53m MDS and AML, and the combination was potentially evaluable for response after 6 treatment cycles (ITT population).
Journal ArticleDOI
Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments
Stefania Cuzzubbo,Sara M. Mangsbo,Divya Nagarajan,Kinana Habra,Alan Graham Pockley,Stephanie E. B. McArdle +5 more
TL;DR: A review of adjuvants for cancer vaccines can be found in this article, where they have been classified into two categories: those that depot antigens (e.g., mineral salts such as aluminum hydroxide, emulsions, liposomes) and those that act as immunostimulants (Toll Like Receptor agonists, saponins, cytokines).
Journal ArticleDOI
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Joshua R D Pearson,Stefania Cuzzubbo,Simon McArthur,Lindy G. Durrant,Jason Adhikaree,Chris J. Tinsley,A. Graham Pockley,Stephanie E. B. McArdle +7 more
TL;DR: This review highlights the immunosuppressive mechanisms employed by GBM cancers and examines potential immunotherapeutic treatments that can overcome these significant immunOSuppressive hurdles.